CO5560578A2 - Derivados de quinazolina como inhibidores de src tirosina cinasa - Google Patents

Derivados de quinazolina como inhibidores de src tirosina cinasa

Info

Publication number
CO5560578A2
CO5560578A2 CO05042313A CO05042313A CO5560578A2 CO 5560578 A2 CO5560578 A2 CO 5560578A2 CO 05042313 A CO05042313 A CO 05042313A CO 05042313 A CO05042313 A CO 05042313A CO 5560578 A2 CO5560578 A2 CO 5560578A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
carbamoyl
alkylamino
hydrogen
Prior art date
Application number
CO05042313A
Other languages
English (en)
Inventor
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5560578A2 publication Critical patent/CO5560578A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Un derivado de quinazolina de la Fórmula 1 en donde Z es un grupo O, S, SO, SO2, N(R2) ó C(R2)2 en donde cada grupo R2, los cuales pueden ser los mismos o diferentes, es hidrógeno o (1-8C)alquilo; m es 0, 1, 2 ó 3; cada grupo R1, los cuales pueden ser los mismos o diferentes, se selecciona de halógeno trifluorometilo, ciano, isociano, nitro, hidroxi, mercapto, amino, formilo, carboxi, carbamoilo, (1-8C)alquilo, (2-8C)alquenilo, (2-8C)alquinilo, (1-6C)alcoxi, (2-6C)alqueniloxi, (2-6C)alquiniloxi, (1-6C)alquiltio, (1-6C)alquilsulfinilo, (1-6C)alquilsulfonilo, (1-6C)alquilamino, di-[(1-6C)alquil]amino, (1-6C)alcoxicarbonilo, N-(1-6C)alquilcarbamoilo, N,N-di-[(1-6C)alquil]carbamoilo, (2-6C)alcanoilo, (2-6C)alcanoiloxi, (2-6C)alcanoilamino, N-(1-6C)alquil-(2-6C)alcanoilamino, (3-6C)alquenoilamino, N-(1-6C)alquil-(3-6C)alquenoilamino, (3-6C)alquinoilamino, N-(1-6C)alquil-(3-6C)alquinoilamino, N-(1-6C)alquilsulfamoilo, N,N-di-[(1-6C)alquil]sulfamoilo, (1-6C)alcanosulfonilamino y N-(1-6C)alquil-(1-6C)alcanosulfonilamino, o de un grupo de la fórmula: Q1 - X1 - en donde X1 es un enlace directo o se selecciona de O, S, SO, SO2, N(R4), CO, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, OC(R4)2, SC(R4)2 y N(R4)C(R4)2, en donde R4 es hidrógeno o (1-8C)alquilo, y Q1 es arilo, aril-( 1-6C)alquilo, (3-7C)cicloalquilo, (3-7C)cicloalquil- (1-6C)alquilo, (3-7C)cicloalquenilo, (3-7C)cicloalquenil-(1-6C)alquilo, heteroarilo, heteroaril-(1-6C)alquilo, heterociclilo o heterociclil-(1-6C)alquilo, o (R1)m es (1-3C)alquilenodioxi,y en donde átomos de carbono adyacentes en cualquier cadena (2-6C)alquileno dentro de un sustituyente R1 se separan opcionalmente por la inserción en la cadena de un grupo seleccionado de O, S, SO, SO2, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, CH=CH y C=C en donde R5 es hidrógeno o (1-8C)alquilo o, cuando el grupo insertado es N(R5), R5 puede ser también (2-6C)alcanoilo,y en donde cualquier grupo CH2=CH- ó HC=C- dentro de un sustituyente R1 lleva opcionalmente en la posición terminal CH2= o HC= un sustituyente seleccionado de halógeno carboxi, carbamoilo, (1-6C)alcoxicarbonilo, ...
CO05042313A 2002-11-04 2005-05-03 Derivados de quinazolina como inhibidores de src tirosina cinasa CO5560578A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292736 2002-11-04
EP03290900 2003-04-10

Publications (1)

Publication Number Publication Date
CO5560578A2 true CO5560578A2 (es) 2005-09-30

Family

ID=32313852

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05042313A CO5560578A2 (es) 2002-11-04 2005-05-03 Derivados de quinazolina como inhibidores de src tirosina cinasa

Country Status (28)

Country Link
US (1) US7462623B2 (es)
EP (1) EP1562955B1 (es)
JP (2) JP4593464B2 (es)
KR (1) KR101089462B1 (es)
AR (1) AR041884A1 (es)
AT (1) ATE387451T1 (es)
AU (1) AU2003278383B2 (es)
BR (1) BR0315756A (es)
CA (1) CA2503371C (es)
CO (1) CO5560578A2 (es)
CY (1) CY1108061T1 (es)
DE (1) DE60319410T2 (es)
DK (1) DK1562955T3 (es)
EG (1) EG24957A (es)
ES (1) ES2300619T3 (es)
HK (1) HK1079195A1 (es)
IL (1) IL168013A (es)
IS (1) IS2568B (es)
MX (1) MXPA05004858A (es)
MY (1) MY137835A (es)
NO (1) NO331951B1 (es)
NZ (1) NZ539408A (es)
PL (1) PL215161B1 (es)
PT (1) PT1562955E (es)
RU (1) RU2350618C2 (es)
SI (1) SI1562955T1 (es)
TW (1) TWI320786B (es)
WO (1) WO2004041829A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
JP4638436B2 (ja) 2003-09-26 2011-02-23 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターおよびその使用
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
TWI577664B (zh) 2009-01-16 2017-04-11 艾克塞里克斯公司 Ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR101882328B1 (ko) 2010-09-27 2018-07-27 엑셀리시스, 인코포레이티드 거세-저항성 전립선 암 및 골형성성 뼈전이의 치료용 met 및 vegf 이중 억제제들
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (ko) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
DE69734149T2 (de) * 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU733551B2 (en) * 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
AU8816298A (en) * 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
PT1117659E (pt) 1998-09-29 2004-04-30 Wyeth Corp Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
CN1161352C (zh) 1998-10-08 2004-08-11 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
HU228964B1 (en) * 1999-02-10 2013-07-29 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU763242B2 (en) 1999-09-21 2003-07-17 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
ATE398120T1 (de) * 1999-11-05 2008-07-15 Astrazeneca Ab Neue quinazolin-derivate
JP2003525897A (ja) 2000-03-06 2003-09-02 アストラゼネカ アクチボラグ 治 療
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1274692B1 (en) 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
NZ523987A (en) 2000-08-09 2004-10-29 Astrazeneca Ab Indole, azaindole and indazole derivatives having VEGF inhibiting activity
JP2004505966A (ja) * 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ シンノリン化合物
IL153947A0 (en) 2000-08-09 2003-07-31 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
RU2267489C2 (ru) * 2000-08-21 2006-01-10 Астразенека Аб Производные хиназолина, способ их получения и фармацевтическая композиция
AU2001292138A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
US6939866B2 (en) * 2000-10-13 2005-09-06 Astrazeneca Ab Quinazoline derivatives
JP2004512335A (ja) 2000-10-25 2004-04-22 アストラゼネカ　アクチボラグ キナゾリン誘導体
DE60229046D1 (de) * 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
JP4326328B2 (ja) 2001-07-16 2009-09-02 アストラゼネカ アクチボラグ キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003047582A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives as antitumour agents
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
JP2005536486A (ja) 2002-07-09 2005-12-02 アストラゼネカ アクチボラグ 癌の処置に使用するためのキナゾリン誘導体
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
MXPA05001458A (es) 2002-08-09 2005-06-06 Astrazeneca Ab Combinacion de zd6474, un inhibidor del receptor del factor de crecimiento endotelial vascular, con radioterapia en tratamiento de cancer.
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
EP1592423B1 (en) 2003-02-13 2011-04-20 AstraZeneca AB Combination therapy of zd6474 with 5-fu and/or cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
CA2503371A1 (en) 2004-05-21
PT1562955E (pt) 2008-05-05
MXPA05004858A (es) 2005-07-22
JP4593464B2 (ja) 2010-12-08
KR101089462B1 (ko) 2011-12-07
EP1562955B1 (en) 2008-02-27
RU2005117337A (ru) 2006-01-20
BR0315756A (pt) 2005-09-06
AU2003278383B2 (en) 2007-06-14
EP1562955A1 (en) 2005-08-17
PL215161B1 (pl) 2013-10-31
IS7849A (is) 2005-05-19
MY137835A (en) 2009-03-31
HK1079195A1 (en) 2006-03-31
IL168013A (en) 2013-03-24
RU2350618C2 (ru) 2009-03-27
TW200420567A (en) 2004-10-16
US20060122199A1 (en) 2006-06-08
DE60319410D1 (en) 2008-04-10
US7462623B2 (en) 2008-12-09
KR20050074526A (ko) 2005-07-18
EG24957A (en) 2011-02-28
DE60319410T2 (de) 2009-02-19
NO20051900L (no) 2005-06-01
NO331951B1 (no) 2012-05-14
TWI320786B (en) 2010-02-21
CY1108061T1 (el) 2014-02-12
PL376255A1 (en) 2005-12-27
ATE387451T1 (de) 2008-03-15
AU2003278383A1 (en) 2004-06-07
DK1562955T3 (da) 2008-06-02
CA2503371C (en) 2011-01-11
AR041884A1 (es) 2005-06-01
JP2010270143A (ja) 2010-12-02
WO2004041829A1 (en) 2004-05-21
NZ539408A (en) 2007-09-28
JP2006506463A (ja) 2006-02-23
ES2300619T3 (es) 2008-06-16
SI1562955T1 (sl) 2008-06-30
IS2568B (is) 2010-01-15

Similar Documents

Publication Publication Date Title
CO5580775A2 (es) Derivados de quinazolina como agentes antineoplasicos
CO5560578A2 (es) Derivados de quinazolina como inhibidores de src tirosina cinasa
CO5580774A2 (es) Derivados de quinazolina como agentes antineoplasicos
CO5690594A2 (es) Derivados de quinazolina como inhibidores de tirosina cinasa
CO5680435A2 (es) Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
EP1620411A4 (en) HEMMER OF ACT ACTIVITY
EP1558586A4 (en) HEMMER OF ACT ACTIVITY
AR041189A1 (es) Piridinas y pirimidinas condensadas con actividad anti-angiogenica, que actuan sobre el receptor de tirosina quinasa
WO2004096130A3 (en) Inhibitors of akt activity
EP1631548A4 (en) INHIBITORS OF AKT ACTIVITY
IL172834A0 (en) Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR052315A1 (es) Derivados de quinazolina utiles para el tratamiento de cancer
PE20010306A1 (es) Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
ES2168383T3 (es) Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.
RU2007148412A (ru) 6,7-ненасыщенное 7-карбамоилзамещенное производное морфинана
PT1210320E (pt) Aminobenzofenonas como inibidores de il-1beta e tnf-alfa
JP2006515593A5 (es)
AR025068A1 (es) Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren

Legal Events

Date Code Title Description
FC Application refused